Newer progestogens

Journal of Family Planning and Reproductive Health Care

Volumn 29, Issue 1, 2003, Pages 13-16

  Rowlands, Sam ^a,b  

^a Health Centre   (United Kingdom)

^b Health Centre   (United Kingdom)

Author keywords

Combined oral contraceptive pills containing newer progestogens have not been shown so far to have appreciable advantages over existing formulations

Indexed keywords

CYPROTERONE ACETATE; DESOGESTREL; DIENOGEST; DROSPIRENONE; ELCOMETRINE; ESTROGEN; ETHINYLESTRADIOL; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TRIMEGESTONE;

ACNE; ALOPECIA; AMENORRHEA; BINDING AFFINITY; BLEEDING; CLINICAL TRIAL; DATA BASE; DISEASE CLASSIFICATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; HEADACHE; HORMONE ACTION; HUMAN; MASTALGIA; MOOD DISORDER; OLIGOMENORRHEA; RECEPTOR BINDING; REVIEW; SUSTAINED RELEASE PREPARATION; VERTIGO; WEIGHT GAIN;

CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; FEMALE; GREAT BRITAIN; HUMANS; PROGESTINS;

EID: 0037258207     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118903101197188     Document Type: Review

References (34)

1. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996; 51: 188-215.
2. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002; 9: 6-15.
3. Kumar N, Koide SS, Tsong Y-Y, et al. Nestorone: a progestin with a unique pharmacological profile. Steroids 2000; 65: 629-636.
4. Oettel M, Holz C. Hybrid progestins: the example of dienogest. In: Sitruk-Ware R, Mishell DR (eds), Progestins and antiprogestins in clinical practice. New York, NY: Marcel Dekker, 2000; 163-178.
5. Zimmermann T, Dietrich H, Wisser K-H, et al. The efficacy and tolerability of Valette®: a postmarketing surveillance study. Eur J Contracept Reprod Health Care 1999; 4: 155-164.
6. Moore C, Luderschmidt C, Moltz L, et al. Antiandrogenic properties of the dienogest-containing oral contraceptive Valette®. Med Actual 1999; 35(Suppl. C): 69-78.
7. Oelkers W, Berger V, Bolik A. Dihydrospirenone, a new progestogen with antimineralocortcoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991; 73: 837-842.
8. Oelkers W, Helmerhorst FM, Wuttke W, et al. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204-213.
9. Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816-1821.
10. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5: 25-34.
11. Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5: 124-134.
12. van Vloten W, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69(Suppl. 4): 2-15.
13. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10: 561-569.
14. Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone: effect on premenstrual symptoms. J Reprod Med 2002; 47: 14-22.
15. Sitruk-Ware R, Sundaram K. Pharmacology of new progestogens: the 19-norprogesterone derivatives. In: Sitruk-Ware R, Mishell DR (eds), Progestins and antiprogestins in clinical practice. New York, NY: Marcel Dekker, 2000; 153-161.
16. Barbosa I, Coutinho E, Hirsch C, et al. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years. Fertil Steril 1996; 65: 724-729.
17. Coutinho EM, de Souza JC, Athayde C, et al. Multicenter clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate, Uniplant. Contraception 1996; 53: 121-125.
18. Brache V, Faundes A, Alvarez F, et al. Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception 2002; 65: 63-74.
19. Urbancsek J. An integrated analysis of nonmenstrual adverse events with Implanon. Contraception 1998; 58: 109S-115S.
20. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomised comparative trial. Contraception 1994; 49: 56-72.
21. Barbosa I, Coutinho E, Athayde C, et al. The effects of nomegestrol acetate subdermal implant (Uniplant) on carbohydrate metabolism, serum lipoproteins and on hepatic function in women. Contraception 1995; 52: 111-114.
22. Barbosa I, Coutinho E, Athayde C, et al. Androgen levels in women using a single implant of nomegestrol acetate. Contraception 1996; 53: 37-40.
23. Dorflinger LJ. Metabolic effects of implantable steroid contraceptives for women. Contraception 2002; 65: 47-62.
24. Sivin I, Moo-Young A. Recent developments in contraceptive implants at the Population Council. Contraception 2002; 65: 113-119.
25. Fraser IS, Weisberg E, Minehan E, et al. A detailed analysis of menstrual blood loss in women using Norplant® and Nestorone® progestogen-only contraceptive implants or vaginal rings. Contraception 2000; 61: 241-251.
26. Brache V, Mishell DR, Lahteenmaki P, et al. Ovarian function during use of vaginal rings delivering three different doses of Nestorone®. Contraception 2001; 63: 257-261.
27. Laurikka-Routti M, Haukkamaa M, Heikinheimo O. A contraceptive vaginal ring releasing ethinylestradiol and progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry. Contraception 1990; 42: 111-120.
28. Haukkamaa M, Laurikka-Routti M, Heikinheimo O. Transdermal absorption of the progestin ST-1435: therapeutic serum steroid concentrations and high excretion of the steroid in saliva. Contraception 1991; 44: 269-276.
29. Zhang Z, Lundeen SG, Zhu Y, et al. In vitro characterization of trimegestone: a new potent and selective progestin. Steroids 2000; 65: 637-643.
30. Philibert D, Bouchoux F, Degryse M, et al. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 1999; 13: 316-326.
31. Coney P, Washenik K, Langley RGB, et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 2001; 63: 297-302.
32. Levell MJ, Cawood ML, Burke B, et al. Acne is not associated with abnormal plasma androgens. Br J Dermatol 1989; 120: 649-654.
33. Pye RJ, Meyrick G, Pye MJ, et al. Effect of oral contraceptives on sebum excretion rate. BMJ 1977; 2: 1581-1582.
34. Vartiainen M, de Gezelle H, Broekmeulen CJH. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. Eur J Contracept Reprod Health Care 2001; 6: 46-53.